DK2470168T3 - Fremgangsmåder til forebyggelse og behandling af cerebral iskæmi - Google Patents

Fremgangsmåder til forebyggelse og behandling af cerebral iskæmi Download PDF

Info

Publication number
DK2470168T3
DK2470168T3 DK10747777.0T DK10747777T DK2470168T3 DK 2470168 T3 DK2470168 T3 DK 2470168T3 DK 10747777 T DK10747777 T DK 10747777T DK 2470168 T3 DK2470168 T3 DK 2470168T3
Authority
DK
Denmark
Prior art keywords
composition
tocotrienol quinone
cerebral
alpha
subject
Prior art date
Application number
DK10747777.0T
Other languages
English (en)
Inventor
Guy M Miller
Viktoria Kheifets
Original Assignee
Bioelectron Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioelectron Tech Corp filed Critical Bioelectron Tech Corp
Application granted granted Critical
Publication of DK2470168T3 publication Critical patent/DK2470168T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (16)

  1. FREMGANGSMÅDER TIL FOREBYGGELSE OG BEHANDLING AF CEREBRAL ISKÆMI PATENTKRAV
    1. Sammensætning til anvendelse i behandling, forebyggelse og/eller bedring af neuronskade, der er forbundet med et cerebralt, iskæmisk event eller hypoxi hos et pattedyreindivid med behov for en sådan behandling, hvor sammensætningen omfatter en effektiv mængde af en tocotrienolquinon, der er udvalgt fra gruppen bestående af alpha-tocotrienolquinon, beta-tocotrienolquinon, gamma-tocotrienolquinon og delta-tocotrienolquinon, eller en blanding deraf, eller en enkelt stereoisomer eller blanding af stereoisomerer deraf; med det forbehold, at individet ikke lider af en mitokondriesygdom.
  2. 2. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor sammensætningen omfatter en effektiv mængde af alpha-tocotrienolquinon eller en hvilken som helst stereoisomer, eller blanding af stereoisomerer, deraf.
  3. 3. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor det cerebrale, iskæmiske event er sekundært til en okklusion af den cerebrale vaskulatur.
  4. 4. Sammensætning ifølge krav 3 til anvendelse som defineret i kravet, hvor okklusionen skyldes en tromboembolus.
  5. 5. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor den cerebrale iskæmi skyldes en spasme i den koronære vaskulatur.
  6. 6. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor det cerebrale, iskæmiske event er sekundært til et ophør af hjertefunktion, en kardiopulmonal bypassprocedure eller et blødningsevent i den cerebrale vaskulatur.
  7. 7. Sammensætning ifølge krav 2 til anvendelse som defineret i kravet, hvor tocotrienolquinonsammensætningen omfatter mindst ca. 65 % alpha-tocotrienolquinon.
  8. 8. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor sammensætningen endvidere omfatter en farmaceutisk acceptabel bærer.
  9. 9. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor sammensætningen administreres oralt.
  10. 10. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor sammensætningen administreres parenteralt.
  11. 11. Sammensætning ifølge krav 2 til anvendelse som defineret i kravet, hvor sammensætningen omfatter alpha-tocotrienolquinon i et interval fra ca. 1 til ca. 1000 mg pr. kg krops vægt for pattedyreindividet.
  12. 12. Sammensætning ifølge krav 2 til anvendelse som defineret i kravet, hvor sammensætningen omfatter alpha-tocotrienolquinon i et interval fra ca. 1 til ca. 50 mg pr. kg kropsvægt for pattedyreindividet.
  13. 13. Sammensætning ifølge krav 1 til anvendelse som defineret i kravet, hvor neuronskaden er udvalgt fra neuroncelledød, totalt cerebralt infarktvolumen, cerebral iskæmisk skade, cerebralvævsødem og kognitiv dysfunktion.
  14. 14. Sammensætning til anvendelse i behandling og/eller bedring af et cerebralt, iskæmisk event eller hypoxi hos et pattedyreindivid med behov for en sådan behandling, hvor sammensætningen omfatter en effektiv mængde af en tocotrienolquinon, der er udvalgt fra gruppen bestående af alpha-tocotrienolquinon, beta-tocotrienolquinon, gamma-tocotrienolquinon og delta-tocotrienolquinon, eller en blanding deraf, eller en enkelt stereoisomer eller blanding af stereoisomerer deraf; med det forbehold, at individet ikke lider af en mitokondriesygdom, hvor apopleksi er ét af symptomerne på mitokondriesygdommen.
  15. 15. Sammensætning ifølge krav 14 til anvendelse som defineret i kravet, hvor sammensætningen omfatter en effektiv mængde af alpha-tocotrienolquinon eller en hvilken som helst stereoisomer, eller blanding af stereoisomerer, deraf.
  16. 16. Sammensætning ifølge et hvilket som helst af kravene 1-15 til anvendelse som defineret i kravet, hvor alpha-tocotrienolquinonen eller stereoisomeren, eller blandingen af stereoisomerer, deraf, er den eneste aktive bestanddel, der er til stede i en effektiv mængde i sammensætningen.
DK10747777.0T 2009-08-26 2010-08-24 Fremgangsmåder til forebyggelse og behandling af cerebral iskæmi DK2470168T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27526909P 2009-08-26 2009-08-26
PCT/US2010/046503 WO2011025785A1 (en) 2009-08-26 2010-08-24 Methods for the prevention and treatment of cerebral ischemia

Publications (1)

Publication Number Publication Date
DK2470168T3 true DK2470168T3 (da) 2018-05-07

Family

ID=42983642

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10747777.0T DK2470168T3 (da) 2009-08-26 2010-08-24 Fremgangsmåder til forebyggelse og behandling af cerebral iskæmi

Country Status (17)

Country Link
US (3) US20110207828A1 (da)
EP (1) EP2470168B1 (da)
JP (2) JP5785546B2 (da)
CN (1) CN102647981B (da)
AU (1) AU2010286704B2 (da)
BR (1) BR112012004167A2 (da)
CA (1) CA2772294C (da)
DK (1) DK2470168T3 (da)
EA (1) EA028677B1 (da)
ES (1) ES2663709T3 (da)
HU (1) HUE037592T2 (da)
MX (1) MX337990B (da)
NO (1) NO2470168T3 (da)
PL (1) PL2470168T3 (da)
PT (1) PT2470168T (da)
SI (1) SI2470168T1 (da)
WO (1) WO2011025785A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
EA035619B1 (ru) * 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
PL2220030T3 (pl) 2007-11-06 2016-07-29 Bioelectron Tech Corp Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych
EP2237664A4 (en) 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP2303824B1 (en) * 2008-06-25 2015-03-25 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
CA2740773A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
WO2010051277A1 (en) 2008-10-28 2010-05-06 Edison Pharmaceuticals, Inc. Process for the production of alpha-tocotrienol and derivatives
CA2777479C (en) 2009-04-28 2017-10-17 Ptc Therapeutics, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
CA2797644A1 (en) * 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
AU2011245384C1 (en) * 2010-04-27 2016-09-01 Bioelectron Technology Corporation Formulations of quinones for the treatment of ophthalmic diseases
JP5809296B2 (ja) 2011-03-03 2015-11-10 シーチェイド ファーマシューティカルズ，インコーポレーテッド 抗真菌薬及びそれらの使用
US9464016B2 (en) 2011-06-14 2016-10-11 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
CA2842486C (en) 2011-07-19 2022-09-06 Edison Pharmaceuticals, Inc. Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
GB201117808D0 (en) * 2011-10-14 2011-11-30 Siemens Medical Solutions SUV correction following dose infiltration
KR102236462B1 (ko) * 2012-03-19 2021-04-08 시다라 세라퓨틱스, 인코포레이티드 에키노칸딘 계열의 화합물에 대한 투여 용법
CA2883879A1 (en) * 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
KR20150082109A (ko) * 2012-11-13 2015-07-15 고다겐 파마슈티컬스 피티와이 엘티디 토코트리에놀의 경점막 전달
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
JP2016515526A (ja) 2013-03-15 2016-05-30 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
RU2578451C1 (ru) * 2014-12-09 2016-03-27 Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Амурская Государственная Медицинская Академия" Министерства Здравоохранения Российской Федерации Способ повышения устойчивости головного мозга к ишемии во время реконструктивных операций на брахиоцефальных артериях
HUE058877T2 (hu) 2014-12-16 2022-09-28 Ptc Therapeutics Inc (R)-2-hidroxi-2-metil-4-(2,4,5-trimetil-3,6-dioxociklohexa-1,4-dienil)butánamid polimorf és amorf alakjai
JP7117241B2 (ja) 2015-12-16 2022-08-12 ピーティーシー セラピューティクス， インコーポレイテッド 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
ES2955711T3 (es) 2016-03-16 2023-12-05 Cidara Therapeutics Inc Regímenes de dosificación para el tratamiento de infecciones fúngicas
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
CA3069423C (en) 2017-07-12 2025-04-15 Napp Pharmaceutical Group Limited Formulations for the treatment of fungal infections
BR112021000018A2 (pt) * 2018-07-03 2021-07-06 Venturis Therapeutics Inc composições e métodos para tratamento de acidente vascular cerebral
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
HUE066196T2 (hu) 2018-10-17 2024-07-28 Ptc Therapeutics Inc 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére
IL291898B1 (en) 2019-10-04 2026-06-01 Stealth Biotherapeutics Inc Quinone-, hydroquinone-, and naphthoquinone- analogs of quinone for the treatment of mitochondrial disorders
CN114729018A (zh) * 2019-10-17 2022-07-08 宾州研究基金会 再生功能神经元以治疗出血性中风
CA3176909A1 (en) 2020-04-03 2021-10-07 Stealth Biotherapeutics Inc. Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia
MX2023003655A (es) 2020-09-29 2023-06-22 Neuexcell Therapeutics Inc Vector neurod1.
JP2023553728A (ja) * 2020-12-22 2023-12-25 コーニンクレッカ フィリップス エヌ ヴェ 血管狭窄の位置特定
CN113066113B (zh) * 2021-04-27 2022-01-11 河北医科大学第二医院 自发性高血压大鼠脑模板和地图集的构建方法及设备
EP4366700A1 (en) 2021-07-08 2024-05-15 PTC Therapeutics, Inc. Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5938203B2 (ja) * 1976-04-26 1984-09-14 エーザイ株式会社 補酵素ｑを主成分とする脳循環障害治療剤
US5872108A (en) * 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US6232060B1 (en) * 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) * 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
ID26335A (id) 1997-11-17 2000-12-14 Lipogenic Inc Metoda untuk mencegah restenosis dengan menggunakan tokotrienol
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6528042B1 (en) * 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6346544B2 (en) * 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
DE10034233A1 (de) * 2000-07-14 2002-01-24 Basf Ag Tocotrienolchinon-Cyclisierungsprodukte
US20020132845A1 (en) * 2000-12-15 2002-09-19 Miller Guy Michael Compositions and methods for the prevention and treatment of tissue ischemia
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6608196B2 (en) * 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
AU2002327517B2 (en) * 2001-08-21 2008-04-17 Johnson & Johnson Consumer Companies, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
US20040152764A1 (en) * 2001-12-14 2004-08-05 Miller Guy M. Compositions and methods for the prevention and treatment of cerebral ischemia
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US6653346B1 (en) * 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
JP4599292B2 (ja) * 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
WO2005033092A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
EA035619B1 (ru) * 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
JP2009508867A (ja) * 2005-09-15 2009-03-05 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体
EP1986636B1 (en) * 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
WO2008086025A2 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
PL2220030T3 (pl) * 2007-11-06 2016-07-29 Bioelectron Tech Corp Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych
WO2009088572A2 (en) * 2008-01-07 2009-07-16 Centocor, Inc. Method of treating erythropoietin hyporesponsive anemias
EP2237664A4 (en) * 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
WO2009111576A2 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP2262519A4 (en) * 2008-03-05 2011-03-23 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCING DISORDERS WITH REDOXACTIVE THERAPEUTICS
EP2310038A4 (en) * 2008-05-15 2012-03-14 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCE OF IMPROVENCE WITH COMPOUNDS WITH ERYTHROPOETIN EFFECT
WO2009143268A2 (en) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
EP2303824B1 (en) * 2008-06-25 2015-03-25 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
WO2010005989A1 (en) * 2008-07-09 2010-01-14 Edison Pharmaceuticals, Inc. Dermatological compositions with anti-aging and skin even-toning properties
US20100029784A1 (en) * 2008-07-30 2010-02-04 Hinman Andrew W Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
EP2344142B1 (en) * 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
CA2740773A1 (en) * 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
WO2010051277A1 (en) * 2008-10-28 2010-05-06 Edison Pharmaceuticals, Inc. Process for the production of alpha-tocotrienol and derivatives
CA2777479C (en) * 2009-04-28 2017-10-17 Ptc Therapeutics, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
EA201101576A1 (ru) * 2009-04-28 2012-04-30 Эдисон Фармасьютикалз, Инк. Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний
WO2010126910A1 (en) * 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
JP2012531411A (ja) * 2009-06-25 2012-12-10 アンペア ライフ サイエンシーズ，インコーポレイテッド トコトリエノールまたはトコトリエノール濃縮抽出物を用いた広汎性発達障害の処置
CA2797644A1 (en) * 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
EA201201374A1 (ru) * 2010-04-06 2013-04-30 Эдисон Фармасьютикалз, Инк. Лечение атаксии-телеангиэктазии
AU2011245384C1 (en) * 2010-04-27 2016-09-01 Bioelectron Technology Corporation Formulations of quinones for the treatment of ophthalmic diseases
WO2012009271A1 (en) * 2010-07-14 2012-01-19 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
WO2012068552A1 (en) * 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control

Also Published As

Publication number Publication date
MX337990B (es) 2016-03-30
HUE037592T2 (hu) 2018-09-28
SI2470168T1 (en) 2018-05-31
BR112012004167A2 (pt) 2016-03-29
EA201200355A1 (ru) 2012-07-30
PL2470168T3 (pl) 2018-06-29
EP2470168A1 (en) 2012-07-04
JP5785546B2 (ja) 2015-09-30
JP2013503168A (ja) 2013-01-31
CN102647981B (zh) 2016-09-28
EA028677B1 (ru) 2017-12-29
CA2772294A1 (en) 2011-03-03
AU2010286704A1 (en) 2012-03-22
US20110207828A1 (en) 2011-08-25
CN102647981A (zh) 2012-08-22
MX2012002374A (es) 2012-04-10
US20180344667A1 (en) 2018-12-06
WO2011025785A1 (en) 2011-03-03
PT2470168T (pt) 2018-03-28
JP2015091899A (ja) 2015-05-14
NO2470168T3 (da) 2018-06-30
US20170007553A1 (en) 2017-01-12
EP2470168B1 (en) 2018-01-31
CA2772294C (en) 2018-08-21
AU2010286704B2 (en) 2016-10-20
ES2663709T3 (es) 2018-04-16

Similar Documents

Publication Publication Date Title
AU2010286704B2 (en) Methods for the prevention and treatment of cerebral ischemia
US7034054B2 (en) Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US20020132845A1 (en) Compositions and methods for the prevention and treatment of tissue ischemia
JP2015199746A (ja) エピメタボリックシフター、多次元細胞内分子、または環境影響因子を使用する代謝性障害の治療方法
TW202203911A (zh) 細胞老化抑制用組成物及抑制細胞老化的方法
Sarwer-Foner Recognition and management of drug-induced extrapyramidal reactions and “paradoxical” behavioural reactions in psychiatry
Hayes et al. Preserved Left Ventricular Function despite Myocardial Fibrosis and Myopathy in the Dystrophin‐Deficient D2. B10‐Dmdmdx/J Mouse
Sun et al. Kudiezi injection attenuates apoptosis and neuroinflammation for ameliorating angiogenesis via miR-21/PDCD4/NF-κB axis in MCAO/reperfusion rats
WO2011157059A1 (zh) 异类叶升麻苷或其药学上可接受的盐的用途
HK1171665B (en) Methods for the prevention and treatment of cerebral ischemia
HK1171665A (en) Methods for the prevention and treatment of cerebral ischemia
US11185553B2 (en) Pharmaceutical composition for preventing or treating ischemic-reperfusion injury comprising bile acids
US20040152764A1 (en) Compositions and methods for the prevention and treatment of cerebral ischemia
ARON Plasma vitamin A and its clinical significance: a review
CN112807296A (zh) 琥珀酸在诊断或治疗自然流产中的应用
EP4338798A1 (en) Pharmaceutical preparation containing genistein for use in the prevention or treatment of glaucoma and/or ocular hypertension
Ragan et al. Brain injury associated with chronic alcoholism
HK40082585A (en) Composition for suppressing cellular senescence, and method for suppressing cellular senescence
KR20200126354A (ko) 진세노사이드 Rb2를 포함하는 신경세포 보호용 조성물
KR20240033367A (ko) 천삼 추출물을 포함하는 폐암의 예방 및 치료용 조성물
KR20240030281A (ko) 몰약 추출물을 유효성분으로 하는 췌장암의 예방 및 치료용 조성물
CN116832025A (zh) 维拉帕米在制备预防、减轻或延缓椎间盘退变产品中的用途
CN100493507C (zh) 化合物6-糠基氨基嘌呤制备抗雌性生殖器官损伤药物应用
CN115721667A (zh) 三七总皂苷和乙酰天麻素在肌萎缩侧索硬化症中的应用
KR20200042745A (ko) 진세노사이드 Rb2를 포함하는 신경세포 보호용 조성물